REPLIMUNE GROUP, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent
REPLIMUNE GROUP, INC. (REPL) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent of -1.00% for the 12-month period ending 2022-03-31, per its 10-K filed 2022-05-19.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2022-05-19
- REPLIMUNE GROUP, INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2022 was -1.00%.
- REPLIMUNE GROUP, INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2021 was -1.90%.
- REPLIMUNE GROUP, INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2020 was -2.20%.
- REPLIMUNE GROUP, INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2019 was -3.10%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month |
|---|---|
| 2022-03-31 | -1.00% 10-K · filed 2022-05-19 |
| 2021-03-31 | -1.90% 10-K · filed 2022-05-19 |
| 2020-03-31 | -2.20% 10-K · filed 2021-05-20 |
| 2019-03-31 | -3.10% 10-K · filed 2020-06-03 |
| 2018-03-31 | -3.80% 10-K · filed 2020-06-03 |
| 2017-03-31 | -7.10% 10-K · filed 2019-06-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |